Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy By Ogkologos - June 16, 2025 661 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DeLLphi-304 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Pomalidomide Viatris January 17, 2024 Predicting future breast cancer with precision March 22, 2021 Adjuvant Treatment with Nivolumab Plus Ipilimumab Combination Fails to Improve DFS... February 22, 2023 Pembrolizumab Combinations Show Promise in mCRPC November 21, 2020 Load more HOT NEWS Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο What is De-escalation Treatment in Cancer Research? Genomic Test Helps Identify Thyroid Nodules That Don’t Require Surgery Hugh Jackman Stops His Show To Bring Woman With Breast Cancer...
